Articles tagged with Immunology
Halle Zhang joins Insilico Medicine to lead global clinical development strategy for the company's oncology portfolio. She brings over 20 years of experience in oncology clinical development and a track record of advancing therapies through registrational trials.
Researchers at MIT and Scripps Research Institute have developed a vaccine that generates a significant population of rare precursor B cells capable of evolving to produce broadly neutralizing antibodies against HIV. The DNA-VLP approach shows potential for inducing broadly neutralizing antibody responses against influenza as well.
Researchers at Salk Institute uncover two transcription factors, ZSCAN20 and JDP2, that determine T cell fate. Turning off these genes reverses T cell exhaustion and restores their ability to kill tumors without losing immune memory. The study challenges the long-standing belief of inevitable immune exhaustion.
Researchers aim to develop a blood test that can determine a person's entire infection history by analyzing T-cell receptor analysis and sequencing. This could provide an indication of which pathogens they are immune to, improving diagnosis and treatment.
Researchers have designed antibodies that recognize a unique sugar found on bacterial cells, providing a potential new treatment for multidrug-resistant hospital-acquired infections. The target of the antibody is pseudaminic acid, a sugar molecule produced exclusively by bacteria and used to evade immune responses.
A study published in Microbiome found that gut microbiome-derived butyrate activates immune cells to enhance vaccine efficacy by promoting T follicular helper (Tfh) cell activity and mucosal antibody production. This discovery highlights the crucial role of gut environment regulation in controlling infections and enhancing vaccine resp...
A new UCLA study clarifies the complex relationship between antibody-driven immunity, viral evolution, and disease severity in SARS-CoV-2. The research found that population-wide antibody responses exert a powerful selective pressure driving the virus to mutate and evade detection.
Engineered yeast cells can mimic real cancer cells and be used to test new cancer immunotherapies much faster and cheaper than before. This new technology enables researchers to assess which CAR T variants are most promising much more quickly, leading to safer and more targeted cancer treatments.
Researchers from Memorial Sloan Kettering Cancer Center reveal the origins of Thetis cells, which play a crucial role in teaching immune system tolerance. The team used single-nucleus DNA sequencing to shed light on pancreatic cancer evolution and identify genetic changes that occur earlier or later in disease progression.
University of Toronto researchers highlight the importance of studying child obesity, gut bacteria, and metabolic conditions to prevent youth-onset diabetes. They emphasize the need for personalized interventions tailored to individual microbiome profiles.
Chronic cellular stress drives liver cell cancer growth, suppressing immune response. Activated ATF6α makes tumors responsive to immunotherapy, opening up new therapeutic approaches.
A new experimental intranasal spray, INNA-051, will be tested in a randomized Phase 2 trial to determine its safety and effectiveness in reducing illness from respiratory viruses. The study aims to enroll 1,100 healthy adults at increased risk of upper respiratory virus infections.
A new platform developed by VIB and UGent researchers allows for more accurate prediction of antibody drug effects in humans. The platform uses a next-generation mouse model that closely reflects human immune biology, enabling better decisions early in drug development.
Researchers developed new chemical probes to track individual enzymes, enabling direct measurement of protein activity and correcting prior limitations. This allows for a clearer picture of molecular logic in cells undergoing programmed cell death, potentially informing drug discovery.
A big data study has identified a specific molecular state of immune cells as associated with the severity of fatigue and respiratory symptoms in Long COVID patients. This finding offers exciting starting points for further research into genetic risk factors and individualised medicine.
Researchers identified statins as a potential booster for cancer immunotherapy by preventing the release of PD-L1-containing sEVs. Statin treatment suppressed UBL3 modification, reduced PD-L1 sorting into sEVs, and improved survival outcomes in lung cancer patients.
Researchers at Salk Institute debut an epigenetic catalog that shows genetic inheritance and life experiences have distinct effects on various types of immune cells, shedding light on individual differences in immune responses and potential new personalized therapeutics.
Researchers have uncovered a new understanding of how cardiac events are interconnected with the brain and nervous/immune systems. They found that sensory neurons in the vagus nerve detect injury and transfer signals to dedicated brain structures, leading to activation of the immune system.
Researchers identified Fab antibody fragments that target the IgE Cε2 domain, effectively stripping IgE from mast cells. The most potent Fab clones showed rapid efficacy in cellular assays and in vivo anaphylaxis models, demonstrating potential as a next-generation anti-allergy therapy.
The cGAS-STING pathway plays a crucial role in detecting cellular DNA, triggering type I interferons and cytokines, and modulating immune responses. Its therapeutic potential is being explored in cancer and various diseases, with promising preclinical evidence suggesting its potential as a target for next-generation immunotherapies.
Salk Institute scientists discover that dietary supplementation of the amino acid methionine protects infected mice against inflammation-related wasting, blood-brain barrier dysfunction, and death. Methionine boosts kidney filtration, reducing circulating cytokine levels and improving disease outcomes.
Researchers found that TL1A, a key immune signaling protein, stimulates the growth of new white blood cells in the bone marrow, which then promote tumor formation in the gut. The study suggests that blocking TL1A activity could be an effective strategy to treat IBD and prevent associated colorectal tumors.
The University of Texas MD Anderson Cancer Center has made significant advancements in cancer care through its collaborative efforts between clinicians and scientists. These breakthroughs include an immune-targeting vaccine that shows promise in intercepting cancer in patients with Lynch Syndrome, a novel immunotherapy that demonstrate...
Researchers at the University of Missouri are developing AI models to accurately detect melanoma by analyzing images of skin abnormalities. The technology can help dermatologists identify cases that may require closer attention, leading to earlier treatment and improved health outcomes.
Researchers identified a distinct population of activated CD38+ HLA-DR+ CD8+ T cells that expands in patients at risk for acute graft-versus-host disease (aGVHD). Tracking this subset can predict disease onset and guide treatment, with targeted therapy offering a promising avenue for precise intervention.
Researchers found identical bacterial strains in the mouth and gut of patients with advanced chronic liver disease, suggesting oral bacteria colonize the gut. These bacteria can damage the intestinal barrier, compromising gut health.
Salk Institute scientists found distinct disease courses and tolerance mechanisms in younger and older mice with sepsis, indicating a need for age-tailored therapies. The study suggests that future treatments may focus on controlling infection-generated damage rather than just targeting the pathogen.
A recent Buck Institute study revealed that spaceflight accelerates aging due to changes in immune cell composition and epigenetic markers. However, researchers also found evidence of intrinsic rejuvenation factors that can counteract these age-accelerating stressors.
Research reveals that fat located near the colon contains an unusually high number of inflammatory fat cells and immune cells, suggesting a unique function in communicating with the immune system in the gut region. This tissue may be an adaptation to the gut microbiome and could contribute to amplifying or sustaining inflammation.
Researchers identify a concrete biological mechanism that triggers MS, focusing on B cells and Epstein-Barr virus. This understanding may help guide future strategies to prevent or treat MS.
Researchers discovered a previously unknown interplay between wheat's resistance genes and fungal disease factors. The study found that powdery mildew fungus overcomes resistance by modifying recognized effectors, but a new approach could slow down its development by combining targeted resistance genes.
Scientists at VIB and KU Leuven discovered a molecular process that enables motor neurons to maintain protein production, which fails in ALS. By restoring protein synthesis in axons, they reduced disease-related damage in ALS models.
Researchers have discovered that feline infectious peritonitis virus infects a broader range of immune cells, including B lymphocytes and T lymphocytes. The findings suggest that the virus can persist in these cells even after treatment, potentially leading to long-term immune problems.
Georgetown University researchers discovered a method to enhance the function of T cells, making them more effective in killing cancer cells. By inhibiting PARP, an enzyme that detects DNA abnormalities, scientists can boost the body's immune response against tumors.
Melanie Rutkowski's pioneering research may lead to novel immunotherapy treatments for ovarian cancer by understanding how faulty cellular signaling interacts with the microbiome. The grant aims to enhance immune system's ability to kill cancer cells and improve patient outcomes.
Researchers have developed a new way to boost the immune system's response to cancer by using specially engineered antibodies. The antibodies work by clustering multiple immune cell receptors, amplifying the signal that tells T cells to attack cancer cells.
A Mizzou researcher developed an antibody that attaches to and lights up EphA2 protein in cancerous tumors, allowing for non-invasive detection and identification of patients who can benefit from targeted treatments. This innovation could save time and money while advancing precision medicine.
Researchers discovered that GBS interacts with C. albicans, increasing the risk of severe and fatal infections in newborns and making standard treatments less effective. The co-infection can also reduce the effectiveness of existing GBS treatments.
Researchers found that male fish exposed to vitamin C and potassium perchlorate showed improved fertility and less damage to their testes compared to those exposed only to the chemical. The study suggests a potential safeguard for individuals regularly exposed to these chemicals, including military personnel.
A University of Toronto-led study has discovered a potential biomarker linked to multiple sclerosis disease progression that could help identify patients most likely to benefit from new drugs. The findings were validated in both mouse models and humans, suggesting a possible surrogate marker for leptomeningeal inflammation.
Two studies found that elevated bacteria levels in tumors weaken immune response, driving resistance to immunotherapy. Researchers are now exploring how to identify patients most likely to benefit from immunotherapy and develop targeted interventions to restore its effectiveness.
Researchers developed a soft, wireless implant that modulates the splenic nerve to restore immune balance in patients with chronic inflammatory diseases. The device showed excellent biocompatibility and reduced inflammation in a rat model of chronic colitis.
Researchers discovered a mechanism allowing melanoma cancer cells to paralyze immune cells by secreting extracellular vesicles, which can disrupt immune cell activity and even kill them. This breakthrough has promising therapeutic implications, enabling strengthening of immune cells and blocking molecules that enable vesicle adhesion.
Research finds that oral bacterium Fusobacterium nucleatum is associated with increased disability in multiple sclerosis patients. Studies suggest a potential 'oral-brain axis' where oral inflammation influences neuroinflammatory disease severity.
Recent advances in immunotherapy have transformed multiple myeloma treatment, offering durable survival benefits. Emerging targets such as regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages are being explored to enhance treatment efficacy.
A new study from Texas A&M University reveals that circadian disruptions change the structure of mammary glands, weaken immune defenses, and fuel aggressive breast cancer. Disabling an immune checkpoint molecule called LILRB4 helps restore the immune system's ability to fight back.
Researchers outline breakthrough strategies to address poor infiltration of CAR-T cells into solid tumor microenvironments. Vascular normalization and chemokine modulation enhance T cell penetration, while combination therapies with chemotherapy and oncolytic viruses amplify results.
A new class of engineered extracellular vesicles can induce antigen-specific regulatory T cells, potentially paving the way for next-generation therapies for autoimmune and allergic diseases. The system uses peptide-MHC complexes to display disease-relevant antigens, allowing for precise control over immune responses.
Researchers have identified an effective strategy to reduce structural liver damage and improve hepatic vascular function in cirrhosis. Blocking the PAF-R receptor can help rebalance immune and inflammatory responses within the liver.
Alveolar macrophages, once seen as peacekeepers in the lung, can actually fuel inflammation during allergic reactions. These cells send signals that attract other immune cells, leading to worsened allergic reactions and potentially life-threatening conditions like asthma.
Scientists have created a detailed single-cell map of asymptomatic dengue virus infections, revealing distinct immune responses that help protect individuals from the virus without symptoms. The findings could guide the development of safer and more effective dengue vaccines.
Research from the University of Basel found that individual genetic differences can make antibody-based therapies ineffective in some people. The study analyzed thousands of genetic sequences and discovered a large number of naturally occurring variations in amino acid sequences, which can render treatments ineffective.
Researchers have developed an ultrasensitive liquid biopsy platform to predict and monitor immunotherapy response in advanced cancer patients. The study shows that lower levels of circulating tumor DNA (ctDNA) at baseline are associated with better progression-free survival and overall survival.
A new artificial intelligence model, ImmunoMatch, predicts correct protein pairings within antibodies, potentially strengthening the immune system. This could lead to new therapeutic treatments for various diseases.
A new diagnostic method using AI and genetic information can accurately identify pneumonia in critically ill patients, distinguishing between infectious and non-infectious causes. The model has been shown to reduce inappropriate antibiotic use by over 80% and could lead to faster diagnosis and improved patient outcomes.
Researchers at UVA Health System discover how traumatic brain injury increases Alzheimer's risk and find a potential prevention strategy using a hollowed-out virus to deliver repair supplies. The approach could help limit neurodegeneration and potentially prevent other neurological diseases.
Researchers developed a new way to stimulate the immune system to attack tumor cells by blocking an immune checkpoint. They created multifunctional molecules called AbLecs, which combine a lectin with a tumor-targeting antibody, and showed they could boost the immune response to cancer cells.
A study by University of Zurich researchers has shed light on the mechanisms that maintain homeostasis with mucosal fungi. The team discovered that the fungus Candida albicans uses a toxin called candidalysin to survive in the mouth, and that interleukin 17-mediated immunity prevents it from growing out of control.
A novel diagnostic approach enables rapid detection of both antibiotic resistance and high virulence in Klebsiella pneumoniae, a microorganism driving the global antibiotic resistance crisis. This breakthrough could support timely, targeted therapy and strengthen infection-control strategies in healthcare settings.
Researchers review how haplo-HSCT overcomes HLA barriers to restore immune homeostasis, with up to 30% GVHD rates reduced. Donor immune cells can be re-educated to accept recipients' bodies as 'self', highlighting a process of immune remodeling.